Recombinant Human MUC1 Protein，His

MUC1, a high molecular weight glycoprotein, is primarily expressed on the surface of epithelial cells and is known for its significant role in protecting mucosal surfaces. Abnormal expression of MUC1 is associated with a variety of cancers, including breast, colorectal, and pancreatic cancers, making it an important target for cancer research and immunotherapy. The interest in MUC1 recombinant proteins has surged due to their potential applications in vaccine development, where they can elicit specific immune responses against tumor cells that express the MUC1 antigen. Furthermore, recombinant MUC1 proteins serve as valuable tools in understanding the molecular mechanisms of cancer progression and metastasis. Recent advancements in recombinant DNA technology, including techniques such as protein engineering and fusion protein generation, have enabled the production of these proteins with enhanced stability and immunogenicity. Researchers are exploring MUC1-based vaccines that can train the immune system to recognize and attack cancer cells more effectively. Additionally, MUC1's role in regulating cell signaling pathways, glycosylation patterns, and interactions with the tumor microenvironment are under investigation, providing insights that could lead to novel therapeutic strategies. As a result, MUC1 recombinant proteins are garnering increased attention in both basic research and clinical contexts, highlighting their potential to contribute significantly to the field of targeted cancer therapy and vaccine design.